Category Archives: Psoriasis

2022 APR 05 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- New research on Biotechnology - Biologics is the subject of a report. According to news reporting originating from Creteil, France, by NewsRx correspondents, research stated, Treatment options for psoriasis (PsO) and psoriatic arthritis (PsA) have evolved significantly throughout the era of biologics. Clinical trials are inadequate to assess the relative long-term efficacy of biologics and are often insufficient regarding safety.

Our news editors obtained a quote from the research from University Paris Est Creteil, To assess the long-term persistence of different biologic classes to treat PsO and PsA. This nationwide cohort study involved the administrative health care database of the French health insurance scheme linked to the hospital discharge database. All adults with PsO and PsA who were new users of biologics (not in the year before the index date) from January 1, 2015, to May 31, 2019, were included and followed up through December 31, 2019. Patients hospitalized for PsA in the PsO cohort and for PsO in the PsA cohort in the year before the index date were excluded. Data were analyzed from June 1 to October 31, 2021. Persistence was defined as the time from biologic therapy initiation to discontinuation and was estimated using the Kaplan-Meier method. Comparison of persistence by biologic class involved using propensity score-weighted Cox proportional hazards regression models and adjustment on specific systemic nonbiologics (time-dependent variables). A total of 16 892 patients with PsO were included in the analysis (mean [SD] age, 48.5 [13.8] years; 9152 men [54.2%] men). Of these, 10 199 patients (60.4%) started therapy with a tumor necrosis factor (TNF) inhibitor; 3982 (23.6%), with an interleukin 12 and interleukin 23 (IL-12/23) inhibitor; and 2711 (16.0%), with an interleukin 17 (IL-17) inhibitor. An additional 6531 patients with PsA (mean [SD] age, 49.1 [12.8] years; 3565 [54.6%] women) were included; of these, 4974 (76.2%) started therapy with a TNF inhibitor; 803 (12.3%), with an IL-12/23 inhibitor; and 754 (11.5%), with an IL-17 inhibitor. Overall 3-year persistence rates were 40.9% and 36.2% for PsO and PsA, respectively. After inverse probability of treatment weighting and adjustment, the IL-17 inhibitor was associated with higher persistence compared with the TNF inhibitor for PsO (weighted hazard ratio [HR], 0.78 [95% CI, 0.73-0.83]) and PsA (weighted HR, 0.70 [95% CI, 0.58-0.85]) and compared with the IL-12/23 inhibitor for PsA (weighted HR, 0.69 [95% CI, 0.55-0.87]). No difference between the IL-17 inhibitor and IL-12/23 inhibitor for PsO was noted. The IL-12/23 inhibitor was associated with higher persistence than the TNF inhibitor for PsO (weighted HR, 0.76 [95% CI, 0.72-0.80]), with no difference observed for PsA. The findings of this cohort study suggest that IL-17 inhibitors are associated with higher treatment persistence than the TNF inhibitor for PsO and PsA. Interleukin 17 inhibitors were also associated with higher persistence than the IL-12/23 inhibitor for PsA, with no difference for PsO.

According to the news editors, the research concluded: However, the persistence rates of all biologics remained globally low at 3 years.

This research has been peer-reviewed.

For more information on this research see: Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database. JAMA Dermatology, 2022. JAMA Dermatology can be contacted at: Amer Medical Assoc, 330 N Wabash Ave, Ste 39300, Chicago, IL 60611-5885, USA.

The news editors report that additional information may be obtained by contacting Laetitia Penso, EpiDermE, University Paris Est Creteil, Creteil, France. Additional authors for this research include Laura Pina Vegas, Pascal Claudepierre and Emilie Sbidian.

Publisher contact information for the journal JAMA Dermatology is: Amer Medical Assoc, 330 N Wabash Ave, Ste 39300, Chicago, IL 60611-5885, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)

View original post here:
University Paris Est Creteil Reports Findings In Biologics (Long-term Persistence Of First-line Biologics For Patients With Psoriasis And Psoriatic...

WESTLAKE VILLAGE, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.(Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the enrollment of the last subject in its ARRECTOR pivotal Phase 3 trial of topical roflumilast foam in adolescents and adults with scalp and body psoriasis. Roflumilast foam is a once-daily, topical formulation of a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor (roflumilast). The foam formulation was designed to treat all areas of the body, including the face and particularly hair-bearing areas such as the scalp. If successful, the Company believes that this trial will provide sufficient basis to file a supplemental New Drug Application (sNDA) in the U.S. for roflumilast foam in scalp and body psoriasis.

Scalp psoriasis occurs in approximately 40% of individuals with plaque psoriasis and can cause physical and emotional distress, with 97% of individuals with scalp psoriasis reporting that the condition impacts their daily life.i

The scalp and hair-bearing areas of the body create unique treatment challenges, not easily solved through creams or ointments, and often requiring patients to use multiple therapies, complicated treatment regimens or resort to expensive systemic or biologic therapies. This can result in lack of compliance to treatment and worsening symptoms. Roflumilast foam has been formulated to overcome these challenges and provide a once-daily treatment option for use on all areas of the body, said Patrick Burnett, MD, PhD, FAAD. We are proud of the continued execution of our clinical development program as demonstrated by the completion of enrollment in a second pivotal phase 3 program for roflumilast foam this year. More importantly, we move one step closer to providing an important treatment option to millions of individuals impacted by scalp psoriasis.

About ARRECTORThe A Randomized tRial Employing topiCal roflumilasT foam to treat scalp psORiasis (ARRECTOR) study is a parallel group, double blind, vehicle-controlled pivotal Phase 3 study of the safety and efficacy of roflumilast foam 0.3% or a matching vehicle administered once-daily in subjects with scalp and body psoriasis ages 12 and older. A total of 432 subjects have enrolled in the study. The co-primary endpoints of the study are the proportion of subjects achieving Scalp-Investigators Global Assessment (IGA) success and the proportion of subjects achieving Body-IGA success, with IGA success defined as an IGA score of clear or almost clear plus a 2-point improvement from baseline after eight weeks.

About Scalp and Body PsoriasisScalp psoriasis is a manifestation of plaque psoriasis characterized by raised, red areas of skin (plaques) covered with a silver or white scale that occurs in the hair-bearing area of the scalp and sometimes extending to the forehead, back of the neck, or behind or inside the ears. Patients with scalp psoriasis commonly have plaques on other areas of the body as well. Approximately 40 percent of the estimated 8.6 million Americans with plaque psoriasis have involvement of the scalp. Scalp psoriasis plaques are identical to psoriatic plaques on other areas of the body; however, topical treatment of scalp plaques is complicated by the difficulty of delivering topical drugs under the hair and onto the skin. As with psoriatic plaques on other parts of the body, psoriasis on the scalp is often itchy and is sometimes painful. Scalp psoriasis can also be associated with hair loss, likely due to damage to the hair from excessive scratching, rubbing, or combing of the affected area. Often, patients require two or more medications to manage their disease when they have scalp involvement.

About Topical Roflumilast Foam Topical roflumilast foam is a once-daily, topical formulation of a highly potent and selective PDE4 inhibitor (roflumilast), which the Company is developing for both seborrheic dermatitis and scalp and body psoriasis. The unique foam formulation is designed to penetrate and treat inflammatory dermatoses in hair-bearing areas of the body, such as the scalp, although it is usable on all areas of the body. Arcutis has also submitted a New Drug Application (NDA) for a closely related cream formulation of topical roflumilast for the treatment of plaque psoriasis, with a Prescription Drug User Fee Actaction date of July 29, 2022. Roflumilast has been approved by the U.S. Food and Drug Administration (FDA) for oral treatment to reduce the risk of exacerbations of chronic obstructive pulmonary disease (COPD) since 2011. PDE4 is an intracellular enzyme that increases the production of pro-inflammatory mediators and decreases production of anti-inflammatory mediators; it has been implicated in a wide range of inflammatory diseases including psoriasis, atopic dermatitis, and COPD. PDE4 is an established target in dermatology, and other PDE4 inhibitors have been approved by the FDA for the topical treatment of atopic dermatitis and the systemic treatment of plaque psoriasis.

About ArcutisArcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis harnesses our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions, with one NDA under review with the FDA and three Phase 3 clinical data readouts anticipated by the end of 2022. The companys lead program, topical roflumilast, has the potential to advance the standard of care for plaque psoriasis of the body and scalp, atopic dermatitis, and seborrheic dermatitis. For more information, visitwww.arcutis.comor follow Arcutis on LinkedIn and Twitter.

Forward-Looking StatementsThis press release contains "forward-looking" statements, including, among others, statements regarding the potential for roflumilast to be approved for the treatment of adults and adolescents with scalp and body psoriasis, the potential to use roflumilast foam over a long period of time, or chronically, the potential to use roflumilast foam anywhere on the body, including the face and scalp, and the potential for roflumilast to advance the standard of care in scalp and body psoriasis and other inflammatory dermatological conditions. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the "Risk Factors" section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 22, 2022, as well as our subsequent filings with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Contacts:MediaAmanda Sheldon, Head of Corporate Communicationsasheldon@arcutis.com

InvestorsEric McIntyre, Head of Investor Relationsemcintyre@arcutis.com

i Crowley J. Scalp psoriasis: an overview of the disease and available therapies. J Drugs Dermatol. 2010 Aug;9(8):912-8. PMID: 20684141.

Read the original:
Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasis - GlobeNewswire

Sustained adoption of conventional disease modifying anti-rheumatic drugs (DMARDs), especially in cost sensitive regions, is projected to push the demand forpsoriatic arthritis treatmentin coming years.

Nearly 70% of the psoriasis patient population is prone to psoriatic arthritis, and up to 20% of arthritis patients are susceptible to acquire psoriasis, according to the recent findings of the Arthritis Foundation.

The rate of increasing burden of psoriasis and psoriatic arthritis on healthcare industry has been boosting clinical research in the field of psoriatic arthritis, in recent years.

Request a report sample to gain comprehensive insights at

https://www.futuremarketinsights.com/reports/sample/rep-gb-2718

Role of Strong Product Pipeline & Mounting Clinical Research Investments

Over 20 drugs for psoriasis and psoriatic arthritis are currently in the phase II of pipeline, whereas more than 28 are in phase III of clinical trial, as indicated by the National Psoriasis Foundation. However, around 24 drugs have already received FDA approval for inclusion in the treatment for psoriasis and psoriatic arthritis.

While such a strong product pipeline continues to drive the demand for psoriasis and psoriatic arthritis treatment, a new research points to the shifting focus of several drug manufacturers to competitive pricing strategies, in an effort to attain widespread acceptance in coming years. Recently, Future Market Insights released a new intelligence based on the analysis of global psoriatic arthritis treatment market. The study forecasts a robust over-7% yearly growth for the market in 2022.

Industry Behemoths Cover More than 55% Market Value Share

In a fairly consolidated global landscape of psoriatic arthritis treatment market, more than 55% share of the total revenue is accounted by industry giants such as Novartis AG and AbbVie Inc. that include biologics in their core portfolio. While market leaders are maintaining focus on FDA approvals and clinical trials, research also points to the increasing importance of diverse pricing strategies.

Moreover, prominent players in psoriatic arthritis treatment market are likely to augment investments in R&D of biosimilars, biologics, and TNF (tumor necrosis factor) inhibitors to target regional markets. A number of leading drug manufacturers are also maintaining sizable investments in DMARDs that are scheduled for market entry in next few years. This is perceived as a strong factor improving growth prospects of psoriatic arthritis treatment market, according to the report.

Besides all these, strategic acquisitions, partnerships, and collaborations will remain the preferred expansion strategies adopted by a majority of prominent operators in psoriatic arthritis treatment landscape, says a senior research analyst at the company.

To remain ahead of your competitors, request for a Brochure:

https://www.futuremarketinsights.com/reports/brochure/rep-gb-2718

Demand for Biologics & DMARDs Gaining Momentum

Research-driven understanding of the pathophysiology of psoriatic arthritis is fueling the introduction of innovative therapies in psoriatic arthritis treatment market, triggering innovations among the market participants thereby supporting the growth of psoriatic arthritis treatment market. Targeted biological therapy has been demonstrating a decent success rate in terms of inducing temporary pain relief resultant of psoriatic arthritis, and thus continues to represent an attractive position in the psoriatic arthritis treatment market.

The report says that the demand for biologics accounts for more than 55% share of the global market revenue, whereas DMARDs demand makes up for more than 3/4thof the total market value. Although a majority of psoriatic arthritis patients opt for injectable as a preferred route of administration of psoriatic arthritis treatment, increasing introduction of innovative oral drugs is uplifting the popularity of orally administered psoriatic arthritis treatment.

Development of novel oral treatments for psoriatic arthritis is likely to favor the growth of North Americas market. Growing availability of combination therapies and relatively economical biosimilar antibody therapeutics are identified to be the primary boosters for the growth of Europes market. Collectively, North America and Europe account for over 60% share in the global value of psoriatic arthritis treatment market. The report indicates that the psoriatic arthritis market in Asia Pacific is likely to display high growth potential in the course of next few years.

For any Queries Related with the Report, Ask an Analyst @

https://www.futuremarketinsights.com/ask-question/rep-gb-2718

Why Future Market Insights?

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMIs latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Future Market Insights,Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,Jumeirah Lakes Towers, Dubai,United Arab EmiratesMARKET ACCESS DMCC InitiativeFor Sales Enquiries:sales@futuremarketinsights.comWebsite:https://www.futuremarketinsights.com

Go here to read the rest:
Psoriatic Arthritis (Psa) Treatment Market Growing at a Healthy 7.1% CAGR, and Projected a Valuation - PharmiWeb.com

Hair loss can be hard. For many people, losing something that is a such a big part of their identity can make them feel uncomfortable in their own skin. Some thinning hair is inevitable with aging, but luckily, it can also be caused by many other factors that are more under your control like hormonal imbalances, stress, or even what type of hair brush you use. With so many possible culprits, though, it may seem impossible to get to the root of the problem. But if you're struggling with hair loss in your sixth decade and beyond, it is likely that a common condition is to blame. Read on to discover what could be making you lose your hair if you're over 50, and how to turn things around.

RELATED: If You're Over 65, Not Doing This in the Shower Is Causing Hair Loss.

One of the most common culprits of hair loss after age 50 is inflammation, a natural response in the body that helps protect from infection and diseases. But if you are chronically inflamed, serious health issues can occur. According to Ben Behnam, MD, FASD, and medical director at hair loss treatment brand Happy Head, inflammation can damage the hair follicles, which can cause strands to fall out. Inflammation can also damage the hair shaft, making it difficult for new hair to grow.

Examples of inflammation on the scalp include dandruff, psoriasis, alopecia areata, and redness and flakiness. Each of these conditions varies, but some of the most common symptoms are itchiness, burning, and even hair loss. However, Behnam notes that not all patients will experience these symptoms.

One of the many causes of inflammation in the bodywhich can ultimately lead to hair lossis an autoimmune reaction. An autoimmune reaction is when the body's immune system mistakenly attacks healthy tissue. "This can happen in a number of autoimmune diseases like lupus erythematosus or alopecia areata, both of which can cause patchy hair loss," says Cheryl Rosen, MD, board-certified dermatologist and director of dermatology at BowTiedLife.

Note that these conditions are somewhat rare: Only about 1.5 million Americans have lupus, per the Lupus Foundation of America. And alopecia areata affects about 2.1 percent of Americans, according to the National Alopecia Areata Foundation. Rosen says autoimmune reactions can also be triggered by things like infections, stress, or certain medications.

RELATED: For more beauty advice delivered straight to your inbox, sign up for our daily newsletter.

According to the American Academy of Dermatology Association, psoriasis is an inflammatory skin condition in which your immune system turns over skin cells too quickly, causing scaly patches. A common area for these patches to develop is the scalp. The National Psoriasis Foundation says that about 8 million Americans suffer from this condition.

Dandruff, on the other hand, is a condition that causes the skin on the scalp to flake. According to Mayo Clinic, it can be triggered by dry skin, a yeast-like fungus, or sensitivity to hair products. Per The International Journal of Trichology, the condition impacts around 50 percent of adults.

Hair loss can occur with both psoriasis and dandruff due to intense itching that manually pulls out the hair. The inflammation of the follicle that causes the conditions can also slow or stop hair growth.ae0fcc31ae342fd3a1346ebb1f342fcb

Fortunately, there are treatments available to improve the condition of the scalp and promote new hair growth. Rosen says they include anti-inflammatory medications, topical treatments, and light therapy.

For example, if you have psoriasis, you may be prescribed a topical steroid to reduce your symptoms, says Behnam. If you have dandruff, you may be offered an anti-dandruff shampoo, such as Nizoral, to soothe the inflammation. For cases of alopecia areata, there are injectable drugs available to reduce inflammation. Over time, hair growth can be restored. "If you are suffering from hair loss due to inflammation, talk to your doctor about the best treatment option for you," says Rosen. That way, you can restore your strands to their healthiest state.

RELATED: If Your Hair Is Thinning, This Food Could Be to Blame, Study Says.

Original post:
If You're Over 50, Inflammation Is Making You Lose Your Hair Best Life - Best Life

The immune system is the body's first line of defensewhen infection-causing pathogens invade, the immune system springs into action, launching substances designed to neutralize the invaders. But that process can go haywire, and the immune system can actually attack the body's own tissues and organs. That's what's known as autoimmune disease. There are several of them, and their symptoms can be wide-ranging, from uncomfortable to potentially debilitating. These are the most common signs your body is attacking itself, according to doctors. Read on to find out moreand to ensure your health and the health of others, don't miss these Sure Signs You've Already Had COVID.

Could be: Rheumatoid arthritis

When the immune system attacks the linings of the joints, rheumatoid arthritis can develop, causing painful swelling. Smaller joints tend to be affected first, followed by larger ones; about 40 percent of people affected by rheumatoid arthritis experience symptoms that don't involve the joints, such as issues with the eyes or skin. "In some people, the condition can damage a wide variety of body systems, including the skin, eyes, lungs, heart and blood vessels," says the Mayo Clinic.

Could be: Lupus, Arthritis

"The classic sign of an autoimmune disease is inflammation, which can cause redness, heat, pain and swelling," says the U.S. National Library of Medicine. Inflammation is a hallmark of a number of autoimmune conditions, the most common being lupus, a complex disease most often diagnosed in women between the ages of 15 and 44. It has a wide range of symptoms, including fatigue, fever, joint pain, stiffness and swelling, and a facial rash.

Could be: Multiple sclerosis

Multiple sclerosis is an autoimmune disorder that causes the body's immune system to mistakenly attack its own healthy cells, damaging the sheath that covers the nerves. This can lead to various neurological symptoms. Numbness and tingling is one of the most common first signs, doctors say, as are vision problems (which tend to affect only one eye). Other symptoms include balance problems, trouble walking, stiffness or weakness in the limbs, and fatigue.

RELATED: I Have Omicron and This is What it Feels Like

Could be: Crohn's disease

Crohn's disease is a type of inflammatory bowel disease (IBS) in which the immune system attacks the digestive tract, causing chronic inflammation. That can lead to abdominal pain, diarrhea, blood in the stool, fatigue, weight loss, and even malnutrition. Symptoms can range from mild to severe and might involve any part of the small or large intestine. It's treated with anti-inflammatory drugs, immunosuppressants and antibiotics.

RELATED: 6 Signs You Might Have Multiple Sclerosis

Could be: Psoriasis, Lupus6254a4d1642c605c54bf1cab17d50f1e

Skin-related symptoms are another common sign of autoimmune disorders. A red "butterfly rash" that develops over the nose and both cheeks is a common sign in lupus. In psoriasis, the body's skin cells go into overproduction mode and build up on the skin in rough, red patches or silvery scales. In psoriatic arthritis, joint pain, redness and swelling accompany the scaling. Both conditions are treatable with medication.

RELATED: COVID Symptoms Usually Appear Like This

Could be: Type 1 diabetes

Type 1 diabetes develops when the immune system destroys cells in the pancreas that are responsible for generating insulin, the hormone that helps the body process sugar and turn it into energy. Without that processor, blood sugar can rise to dangerous levels, damaging blood vessels and increasing the risk of heart disease, stroke, dementia, and blindness. Although it's most commonly diagnosed in childhood, type 1 diabetes can develop at any age. Other symptoms include frequent thirst, increased urination, fatigue, constant hunger, and intentional weight loss.

And to protect your life and the lives of others, don't visit any of these 35 Places You're Most Likely to Catch COVID.

Visit link:
Signs Your Body Is Attacking Itself, Say Doctors Eat This Not That - Eat This, Not That

Awards season is in full swing, and now that weve all had some time to digest the Will SmithChris Rock slap at the Oscars last Sunday, its time to turn our collective attention to the Grammys. Below, find all the details you need on how to watch the 2022 Grammy Awards, on TV, livesteam, or online:

The 64th Grammy Awards will be held on Sunday, April 3, at 8 p.m. E.T.

For the first time, this years Grammys will be held in Las Vegas, so expect plenty of ads for casinos and strip jokes from presenters.

The Grammys will be televised live on CBS, and if you have cable, thats probably your easiest route toward taking in all the award-winning performances.

Cable subscribers can stream the Grammys live on cbs.com and the CBS app by logging in with their provider, but if youre a cord-cutter, dont worry, all is not lost: You can access the ceremony through Paramount+, the official streamer of the Grammys, or through subscriptions to Hulu Live TV, YouTubeTV, AT&T TV, and FuboTV. (Pro tip: Take advantage of the free trial that many of these platforms offer!)

Grammys 2022 Red Carpet: See All The Celebrity Dresses, Outfits, And Looks Here

Photo: Getty Images

Jared Leto in Gucci

Read original article here

Go here to read the rest:
How to Watch the 2022 Grammy Awardson TV or Online - Verve Times

The first accurate medical discussion of psoriasis dates back to 1801, but the disease itself is much older. In fact, its very name is borrowed from an ancient Greek word meaning an itchy or scaly condition. About 7 million Americans are plagued by this itching and scaling, and many of them have serious complications involving other organs. Although psoriasis is classified as a dermatologic disease, it doesn't start in the skin, and its damage may be more than skin deep.

At a basic level, psoriasis is a disorder of the immune system. White blood cells called T-helper lymphocytes become overactive, producing excess amounts of cytokines, such as tumor necrosis factor, interleukin-2, and interferon-gamma. In turn, these chemicals trigger inflammation in the skin and other organs. In the skin, the inflammation produces three characteristic findings: widened blood vessels, accumulation of white blood cells, and abnormally rapid multiplication of keratinocytes, the main cells in the outer layer of the skin. In healthy skin, keratinocytes take about a month to divide, mature, migrate to the skin surface, and slough off to make way for younger cells. But in psoriasis, the entire process is speeded up to as little as three to five days. The result is thickened, red skin that sheds silvery scales of keratinocytes that have matured before their time (see Figure 1).

As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.

Link:
Psoriasis: More than skin deep - Harvard Health

A consensus was reach on 20 of the 21 proposals regarding dosing of methotrexate in patients with psoriasis, which investigators of the eDelphi study believed could be use to harmonize the treatment of the drug in affected patients.

As one of the 4 available systemic treatments, methotrexate has been prescribed for psoriasis for over 6 decades, and is also used prominently in the rheumatology field.

However, methotrexate was approved by the US Food and Drug Administration before the introduction of dose ranging studies. As such, a clear dosing regimen for the treatment is lacking.

As such, investigators led by Astrid van Huizen, MD, Department of Dermatology at the University of Amsterdam, conducted the eDelphi study to reach international consensus on the dosing of methotrexate for treating patients with psoriatic disease.

The study consisted of 3 sequential survey rounds that were conducted in September 2020, November 2020, and February 2021. An online consensus meeting occurred following the last survey round in June 2021.

A total of 4500 members of the Skin Inflammation and Psoriasis International Network (SPIN) were invited to participate. Additional emails were sent to 108 national representatives and 35 scientific committee members of the network.

From September 2020 to March 2021, a total of 180 participants worldwide- 30.6% of whom resided in non-Western countries- completed the 3 survey rounds.

Participants voted on 21 individuals proposals on a 9-point scale, 1-3 indicated disagree, 4-6 neither agree nor disagree, and 7-9 being agree.

A majority of participants worked at a university hospital (53.9%) and were experienced in treating patients with psoriasis with methotrexate (91.6%), with more than 10 years of experience.

Among the 251 participants included in the study, 180 (71.7%) completed all 3 survey rounds, and 58 participants (23.1%) joined the conference meeting.

No consensus was achieved regarding increased dosage of folic acid when increasing the dosage of methotrexate, with members of the study citing a lack of conclusive evidence.

However, a consensus was met regarding children and methotrexate dosing, though most proposals were based on studies from rheumatology due to a lack of evidence in dermatology.

The most widely discussed proposals involved patients with frailty. Elderly individuals, individuals with kidney renal dysfunction, liver disorders (eg, nonalcoholic steatohepatitis), ulcerative colitis, history of hepatitis, lack of compliance, gastritis, diabetes, previous cancer, and congestive heart failure were included in the added definition of patients with frailty.

Furthermore, the term patients with frailty was replaced with vulnerable patient, which excluded elderly patients and patients with impaired kidney function.

While a consensus was achieved in the study, investigators believed that additional high-quality studies were needed to support the proposals offered by the group.

Other consensus projects can focus on the screening and monitoring of this drug, how often and which tests should be performed, and whether special precautions are needed in children, elderly individuals, and other subpopulations, the team wrote.

The statement, "International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis," was published online in JAMA Dermatology.

Continued here:
20 Proposals on Methotrexate Dosing in Patients with Psoriasis Discussed - MD Magazine

Who remembers the sweet 9-year-old girl, Yaelle from Dr Pimple Popper? Yaelle was featured on Season 5 during the episode entitled, Cyster Cyster and quickly captivated fans attention with her bubbly and charismatic personality. Unfortunately, she suffered from a serious case of psoriasis that covered her entire body and she went on the show in hope that Sandra Lee could help her.

The epic episode contained many bizarre situations including the twin sisters that both had cysts, however, Yaelle was the stand out star of the show and fans want to know what happened to her and if she managed to get her psoriasis sorted. Keep reading to find out!

BridTV

9139

Lucy and Desi | Official Trailer | Amazon Prime Video

https://i.ytimg.com/vi/Lw1h7olYRTY/hqdefault.jpg

978532

978532

center

22403

Yaelle is from a town called Hotchkiss in Colorado and at just nine years old she had suffered from extreme psoriasis all the way from her arms, neck, legs and head from a very young age and her condition was so bad that she said the skin often clogged up her ears.

The little girl had suffered from the condition since she was a baby, however, it started off only around her eyes and belly button but when she was nine it quickly flared up across her entire body.

Heartbreakingly, Yaelle opened up about how embarrassed she was by her condition and how she would style her hair specifically to try and cover it on her face. Her mom had tried to get her medications and steroids but none of them worked and only seemed to make it worse, so they finally decided to see Dr Lee in hopes of a miracle.

They drove all the way from Colorado to California to see the pimple popper and its safe to say it was worth the trip.

During the consultation, Lee described the many treatment options that were available for Yaelles condition but explained how most are too intense and dangerous.

However, we all know how amazing Dr Lee is and she obviously had a plan. The family had only been used to more old-fashioned treatment methods but Lee was here to introduce them to some new ones.

Dr Lee explained an amazing new medication that was only required to be taken once every three months by injection and said the results are usually spectacular. Yaelle was quick to jump at the opportunity and was very brave while receiving the injection.

At the end of the episode, we got to see Yaelle a few months later and fans were gobsmacked. The transformation was incredible and her psoriasis was almost cleared. Yaelle was over the moon and said she finally felt like me again.

During the episode we heard the pain Yaelles mother was going through from having to see her daughter suffer so much, she opened up about the familys Jewish religion and how they strive to live a self-sustaining, off-grid lifestyle.

The only issue with this was that the mom said it affected her daughter due to them being so far away from most towns it was hard for them to get doctors out and treat her psoriasis.

The family grow their own food and products and Yaelle was clear about how much she loves the outdoors so we are over the moon that she can finally enjoy it to its fullest!

WATCH DR PIMPLE POPPER ON TLC EVERY WEDNESDAY AT 9/8C

ANDGET FREAKY WITH US ONINSTAGRAMANDFACEBOOK

Niamh is a multi-faceted journalist with speciality interests in entertainment, lifestyle and culture. She recently graduated from the University of South Wales with a degree in Journalism and enjoys writing features, reviews and trending news stories.

See original here:
Dr Pimple Popper changed 9-year-old Yaelles life forever with genius treatment - Reality Titbit - Celebrity TV News

The new report by Expert Market Research titled, GlobalPsoriatic Arthritis Treatment MarketReport and Forecast 2021-2026, gives an in-depth analysis global psoriatic arthritis treatment market, assessing the market based on drug class, product type, route of administration, and major regions. The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analysing the market based on the SWOT and Porters Five Forces models.

Request a free sample copy in PDF or view the report summary@https://www.expertmarketresearch.com/reports/psoriatic-arthritis-treatment-market/requestsample

The key highlights of the report include:

Market Overview (2016-2026)

In addition to the rise in biological and biosimilar therapies, there is an increase in the prevalence of psoriatic arthritis and an increase in R&D activities to develop novel drugs for the treatment of psoriatic arthritis. There is also an increase in demand for psoriatic arthritis treatment goods, along with an increase in the elderly population. High treatment costs and a lack of standardised diagnostic technologies, on the other hand, are projected to restrain market expansion.

Industry Definition and Major Segments

Psoriatic arthritis is a spondylarthritis-related inflammatory joint disease caused by psoriasis. Skin and musculoskeletal systems are both affected. Genetics and the environment both play a role in its development. Psoriatic arthritis symptoms include swollen toes, fingers, and joints, and pitted nails and discomfort.

Explore the full report with the table of contents@https://www.expertmarketresearch.com/reports/psoriatic-arthritis-treatment-market

On the basis of its drug class, the market can be widely categorised as:

Based on its product type, the market can be bifurcated as:

The different administration route available for psoriatic arthritis treatment are:

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Market Trends

More than half of the revenue share was captured by biologics in the Psoriatic Arthritis (PsA) Treatment market. The drug class is likely to increase at the fastest rate during the forecast period and maintain its dominance. The segments growth is expected to be bolstered by the good commercial performances of existing products and the upcoming releases of potential pipeline prospects.

North America and Europe accounted for over half of total revenue. North America led the regional markets, mostly due to product sales in the United States. There is also a substantial patient pool and significant manufacturers supporting the PsA treatment market expansion. Asia Pacific is predicted to be one of the fastest expanding areas. Biosimilars are a crucial growth driver in emerging economies including China, India, and South Korea. Regional expansion is also likely to be influenced by overall economic development, healthcare infrastructure improvements, rising disposable income, and consumer awareness.

Key Market Players

The major players in the market are AbbVie Inc., Amgen, Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer, Inc., UCB S.A, and AstraZeneca plc, among others. The report covers the market shares, capacities, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

About Us:

Expert Market Research is a leading business intelligence firm, providing custom and syndicated market reports along with consultancy services for our clients. We serve a wide client base ranging from Fortune 1000 companies to small and medium enterprises. Our reports cover over 100 industries across established and emerging markets researched by our skilled analysts who track the latest economic, demographic, trade and market data globally.

At Expert Market Research, we tailor our approach according to our clients needs and preferences, providing them with valuable, actionable and up-to-date insights into the market, thus, helping them realize their optimum growth potential. We offer market intelligence across a range of industry verticals which include Pharmaceuticals, Food and Beverage, Technology, Retail, Chemical and Materials, Energy and Mining, Packaging and Agriculture.

Media Contact

Company Name: EMR Inc.Contact Person: Steven Luke, Corporate Sales Specialist U.S.A.Email:sales@expertmarketresearch.comToll Free Number: +1-415-325-5166 | +44-702-402-5790Address: 30 North Gould Street, Sheridan, WY 82801, USACity: SheridanState: WyomingCountry: United StatesWebsite:https://www.expertmarketresearch.com

Read More Reports:

Global Calcium Carbide Market:https://www.expertmarketresearch.com/reports/calcium-carbide-market

Global Wireline Services Market:https://www.expertmarketresearch.com/reports/wireline-services-market

Global Oilfield Services Market:https://www.expertmarketresearch.com/reports/oilfield-services-market

Global vegetable protein market:https://www.expertmarketresearch.com/reports/vegetable-protein-market

Global Reishi Mushroom Extract Market:https://www.expertmarketresearch.com/reports/reishi-mushroom-extract-market

Also, CheckProcurement Intelligencewhich provides you with Infallible research solutions.

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

Visit link:
Global Psoriatic Arthritis Treatment Market to be Driven by Rising Incidence of Psoriatic Arthritis and Extreme Symptoms in the Forecast Period of...